Our study demonstrated that the CRHR1 antagonist Antalarmin reduces colonic damage by modulating the mucosal immune system, improving intestinal barrier function and stabilizing gut microbiota in a model of MS. This evidence concerns the gene CRHR1 and myeloid sarcoma.